1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
XOMA Royalty Corporation

XOMA Royalty Corporation

XOMAP
XOMA Royalty CorporationUS flagNASDAQ
24.98
USD
- -
- -
301.34MMarket Cap
XOMA Royalty Corporation
XOMAP
(NASDAQ)

Recent

price

24.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
16.56
8.55
5.21
-0.76
0.53
-0.39
-7.72
0.7
2.16
4.51
7.69
12.53
10.82
7.71
5.17
7.07
9.48
Book Value per Share
16.56
8.55
5.21
-0.76
0.53
-0.39
-7.72
0.7
2.16
4.51
7.69
12.53
9.5
7.71
3.01
3.3
5.79
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
34
58
34
35
19
55
6
53
5
18
29
38
6
5
10
12
8
Sales/Revenue/Turnover
-199.23
-58.35
-152.6
-163.26
-433.31
-64.97
-1,024.3
38.87
-282.05
-21.15
42.25
45.94
-288.93
-493.13
-391.15
97.63
65.01
Operating Margin (%)
6
5
4
3
2
2
1
- -
- -
- -
- -
- -
- -
1
- -
3
3
Depreciation Expense
-69
-33
-71
-124
-38
-21
-54
15
-13
-2
13
16
-17
-41
-14
32
34
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
10.22
- -
- -
- -
0.57
- -
- -
- -
0.32
0.31
Effective Tax Rate (%)
-204.38
-56.26
-210.36
-349.94
-203.02
-37.16
-962.08
27.7
-251.8
-10.79
45.25
41.4
-283.79
-858.15
-135.23
271.97
441.79
Profit Margin (%)
23
42
72
97
47
49
-5
37
42
51
76
84
54
150
101
82
86
Working Capital
14
34
38
35
16
43
25
15
22
28
13
- -
- -
119
107
117
108
LT Debt
24
15
21
-4
3
-2
-47
6
19
44
86
142
124
89
62
84
113
Total Equity
- -
- -
- -
- -
- -
- -
- -
204.82
- -
- -
- -
13.95
- -
- -
- -
5.72
2.27
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
192.49
- -
- -
- -
13.02
- -
- -
- -
22.54
21.38
Return on Capital (%)
-334.46
-169.65
-389.63
- -
- -
- -
- -
- -
-108.61
-6.31
20.27
9.85
-16.99
-43.55
-25.63
35.93
28.57
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
17
15
16
LT Borrowings
94
96
89
LT Finance Leases
21
20
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
326
319
313

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
111
117
119
Cash, Cash Equivalents & STI
47
83
86
Accounts Receivable, Net
4
5
5
Inventories
- -
- -
- -
Total Current Liabilities
28
35
33
Payables & Accruals
7
9
7
ST Debt
17
15
16
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
231.61%
5.7%
35.6%
Free Cash Flow
-94.43%
92.58%
29.68%
Net Income, GAAP
-146.14%
-89.27%
-329.45%
Sales/Revenue/Turnover
102.72%
10.7%
14.09%
Total Cash Common Dividend
- -
- -
-94.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
6
1
2
10
2025
4
5
1
1
12
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Indaptus Therapeutics, Inc. (INDP)
Twist Bioscience Corporation (TWST)
Trevi Therapeutics, Inc. (TRVI)
PaxMedica, Inc. Common Stock (PXMD)
Destiny Pharma plc (DEST.L)
LexaGene Holdings Inc. (0V43.L)
Business
XOMA Royalty Corporation (NASDAQ: XOMA), formerly XOMA Corporation, operates as a biotechnology royalty aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology partners; its portfolio encompasses over 120 such assets spanning multiple therapeutic areas and development stages, including commercial products like VABYSMO (faricimab-svoa) for neovascular age-related macular degeneration and diabetic macular edema, OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate vaginal gel 2%), IXINITY (coagulation factor IX recombinant), and DSUVIA (sufentanil sublingual tablet), as well as early- to mid-stage investigational candidates such as those from partners including Roche, Day One Biopharmaceuticals, Zevra Therapeutics, Rezolute, Gossamer Bio, and Takeda; the company targets development-stage assets with blockbuster potential from well-capitalized partners and royalties on therapies addressing specific patient populations, employing a portfolio approach to mitigate single-asset risk while operating a capital-efficient structure where partners bear all R&D costs. Founded in 1981 and headquartered in Emeryville, California, XOMA Royalty conducts its activities primarily in the United States, Asia Pacific, Europe, and Switzerland, providing non-dilutive, non-recourse funding to sellers for advancing drug candidates or general corporate purposes. Recent developments include the completion of acquisitions for Turnstone Biologics at $0.34 per share plus a contingent value right and HilleVax at $1.95 per share plus a contingent value right; announcements of acquisitions for LAVA Therapeutics, securing interests in partnered assets PF-08046052 (Pfizer) and JNJ-89853413 (Johnson & Johnson), and Mural Oncology at $2.035 to $2.24 per share expected in Q4 2025; acting as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma; a financing arrangement raising up to $140 million with Blue Owl Capital to support repurchases and further acquisitions; and portfolio advancements such as Zevra Therapeutics' MAA submission for arimoclomol in Niemann-Pick Type C, Rezolute's Phase 3 topline data expectations, and Gossamer Bio's Phase 3 trial progress.

Company News

Company News APIChatGPT

  • defenseworld.net

    XOMA (NASDAQ:XOMAP) Stock Price Down 1.5% – Time to Sell?